863 MITTEN ROAD, BURLINGAME, CA
Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Provides Business Update and Reports First Quarter 2026 Financial Results
Board Appointment - Andrew C. Chan Joins Corvus Pharmaceuticals Board
Corvus Pharmaceuticals Enters Amended Sales Agreement with Jefferies for $200M
Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Corvus Pharmaceuticals Enters Underwriting Agreement for Public Offering
Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Other Events
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Additional Securities
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence